Medicinal chemical approaches have been applied to all four of the adenosine receptor
(AR) subtypes (A1, A2A, A2B, and A3) to create selective agonists and antagonists for each …

Despite the progress that has occurred in recent years in the development of therapy, there
is still a need for effective and potent analgesics, especially for the treatment of chronic pain …

The functional role of heteromers of G-protein-coupled receptors is a matter of debate. In the
present study, we demonstrate that heteromerization of adenosine A 1 receptors (A 1 Rs) …

The regulatory actions of adenosine are mediated via four subtypes of G protein-coupled
receptors distinguished as A 1, A 2A, A 2B and A 3 receptors. Their presence on basically …

The purine nucleoside adenosine is consensually identified as a major local regulator of
tissue function especially when energy supply fails to meet cellular energy demand. Due to …

The natural plant alkaloids caffeine and theophylline were the first adenosine receptor (AR)
antagonists described in the literature. They exhibit micromolar affinities and are non …

Chiral bicyclic guanidine 1 was found to be an excellent catalyst for reactions between
anthrones and various dienophiles. The catalyst can tolerate a range of substituents and …

Water-soluble prodrugs of potent, A2A-selective adenosine receptor (AR) antagonists were
prepared. 8-(m-Bromostyryl)-3, 7-dimethyl-1-propargylxanthine (BS-DMPX, 11) and the …

Ever since the discovery of the hypotensive and bradycardiac effects of adenosine,
adenosine receptors continue to represent promising drug targets. First, this is due to the fact …

Adenosine A 2A receptors are putative therapeutic targets for neurological disorders. The
adenosine A 2A receptor antagonist istradefylline is approved in Japan for Parkinson's …